SPIA
GANX icon

Steward Partners Investment Advisory’s Gain Therapeutics GANX Stock Holding History

Steward Partners Investment Advisory’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$1K – 3225
2021
Q3 		$1K Hold
100
– – ﹤0.01% 3070
2021
Q2 		$1K Buy
+100
New +$1.13K ﹤0.01% 6960

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Steward Partners Investment Advisory's GANX Position: Q4 2021 in Review

Steward Partners Investment Advisory sold out of Gain Therapeutics (GANX) in Q4 2021, closing a stake of 100 shares — an estimated $1K sold.

Steward Partners Investment Advisory first reported a position in GANX in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 19 funds tracked by Wall St. Rank hold GANX as of Q4 2021.

  • Steward Partners Investment Advisory reported no remaining Gain Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 100 Gain Therapeutics shares in Q4 2021, an estimated $1K.
  • Steward Partners Investment Advisory first reported a position in Gain Therapeutics in Q2 2021 and held it in 2 quarters.
  • Steward Partners Investment Advisory's Gain Therapeutics position peaked at $1K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2021, filed 8 Feb 2022.